Skip to main content
GutCited

Saccharomyces boulardii per Antibiotic-Associated Diarrhea (AAD)

A

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

In sintesi

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

Key Study Findings

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs Effetto: L. rhamnosus GG used by 91.8% None

Popolazione: Italian primary care pediatricians

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: Pediatric population

Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI Effetto: None None

Popolazione: Pediatric patients with GI disorders

Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None vs: None Outcome: C. difficile infection treatment outcomes Effetto: None None

Popolazione: Patients with C. difficile infection

Randomized Controlled Trial n=47 1 weeks
[A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants …
Dose: None vs: Control Outcome: Gut microbiota composition Effetto: None P<0.017

Popolazione: Children

Key Statistics

25

Studi

5000

Partecipanti

Positive

A

Grado

Referenced Papers

Advances in experimental … 2024 2 citazioni
Advances in experimental … 2019 17 citazioni
The American journal … 2018 46 citazioni
Journal of pediatric … 2016 233 citazioni
Digestive diseases (Basel, … 2016 37 citazioni
The Cochrane database … 2015 233 citazioni
Journal of clinical … 2015 35 citazioni
Expert opinion on … 2014 57 citazioni
Journal of clinical … 2011 432 citazioni
Journal for specialists … 2010 22 citazioni
American journal of … 2010
European journal of … 2009 91 citazioni
Current opinion in … 2009 82 citazioni
Advances in biochemical … 2008 535 citazioni
American family physician 2008
The Journal of … 2007 265 citazioni
The American journal … 2001 648 citazioni
International journal of … 2000 181 citazioni
Clinical infectious diseases … 1998 346 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

Limite massimo: Well-tolerated up to 1,000 mg/day in clinical trials

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Mixed 279
None -- Mixed --
None -- Positive --
None -- Positive --
None -- Positive --
None 1 weeks Positive 47
None 20 weeks Positive 564
None -- Positive --

Momento migliore per l'assunzione: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

Effetti collaterali segnalati

  • Mild gas and bloating
  • Rare: fungemia in critically ill patients with central venous catheters
  • Thirst (yeast may increase water requirements)
  • Very rare: potential environmental contamination risk in ICU settings

Interazioni note

  • Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

Livello di assunzione massimo tollerabile: Well-tolerated up to 1,000 mg/day in clinical trials

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.

Related Evidence

Altri ingredienti per Antibiotic-Associated Diarrhea (AAD)

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.